Departments and specialties

Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery.


Mayo Clinic is an international leader in non-Hodgkin's lymphoma research.

The Hematologic Malignancies Program conducts blood and bone marrow cancer research in coordination with the Mayo Clinic Cancer Center. The Mayo Clinic Cancer Center receives funding from the National Cancer Institute and is designated as a comprehensive cancer center — recognition for an institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.

Areas of research include:

  • Designing and conducting clinical trials to study more effective and less toxic treatments for many different types of lymphoma
  • Developing the Lymph2Cx genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma
  • Studying who is more likely to have a relapse of lymphoma and why

Mayo Clinic Cancer Center is one of a handful of facilities that received a U.S. National Cancer Institute Specialized Program of Research Excellence (SPORE) grant for lymphoma research. Mayo applies that research to developing more effective and less toxic treatments for all forms of lymphoma. Mayo Clinic conducts many clinical trials to test new therapies for the disease.


See a list of publications about non-Hodgkin's lymphoma by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

Research Profiles

Non-Hodgkin's lymphoma care at Mayo Clinic

May 04, 2021

Living with non-hodgkin's lymphoma?

Connect with others like you for support and answers to your questions in the Adolescent & Young Adult (AYA) Cancer support group on Mayo Clinic Connect, a patient community.

Adolescent & Young Adult (AYA) Cancer Discussions

Ampullary cancer: What are the chances of surviving?

1 Replies Sun, Apr 17, 2022

AML - C-kit Mutation, Core binding factor

4 Replies Thu, Mar 03, 2022

See more discussions